SCHEDULE: Morgan Stanley Boosts Royalty Pharma Stake to 9.2%

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported increased beneficial ownership in Royalty Pharma plc, now holding 9.2% and 8.5% respectively.

Summary

• Morgan Stanley reported beneficial ownership of 38,907,011 Class A Ordinary Shares of Royalty Pharma plc.
• This represents 9.2% of the Class A Ordinary Shares outstanding.
• Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley, reported beneficial ownership of 35,864,664 Class A Ordinary Shares.
• This represents 8.5% of the Class A Ordinary Shares outstanding.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of Royalty Pharma plc.

Sentiment

Score: 6

Explanation: The filing is a routine beneficial ownership report indicating a significant, non-control-seeking stake by a major financial institution, which is generally a neutral to slightly positive signal of institutional confidence.

Positives

• The continued significant beneficial ownership by Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., indicates sustained institutional confidence in Royalty Pharma plc.

Negatives

• No negative information regarding Royalty Pharma plc's operations or financial health is presented in this beneficial ownership report.

Risks

• No specific risks to Royalty Pharma plc are detailed in this beneficial ownership report, as it primarily focuses on the reporting entities' ownership stake and intent.

Future Outlook

No forward-looking statements or guidance are provided in this beneficial ownership report.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

The filing reflects continued institutional interest in Royalty Pharma plc, a company focused on acquiring biopharmaceutical royalties, which aligns with broader trends of financial institutions investing in specialized healthcare and life sciences assets.

Comparison to Industry Standards

• Morgan Stanley's beneficial ownership stake of 9.2% in Royalty Pharma plc is a substantial institutional position, aligning with typical large fund holdings in specialized sectors like biopharmaceutical royalties.
• This level of ownership is significant enough to trigger SEC reporting requirements, demonstrating a material investment by a major financial institution.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are mentioned in this beneficial ownership report.

Related Party Transactions

• No related party transactions are disclosed in this filing.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Morgan Stanley may be viewed positively, potentially signaling confidence in Royalty Pharma plc's long-term prospects.

Next Steps

• No specific future actions or milestones for Royalty Pharma plc are mentioned in this beneficial ownership report.

Key Dates

Recommendation

This filing is a routine beneficial ownership report and does not contain information on the company's financial performance, strategic direction, or operational updates that would warrant a change in investment recommendation. It primarily indicates a significant, non-control-seeking institutional stake by Morgan Stanley, which is a neutral to slightly positive signal for existing shareholders.

Keywords

Royalty Pharma, Morgan Stanley, beneficial ownership, SEC filing, Schedule 13G, Class A Ordinary Shares, institutional ownership, biopharmaceutical royalties